Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma

27. marts 2017 opdateret af: Hoffmann-La Roche

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study to Assess the Efficacy and Safety of Oral Vismodegib for the Treatment of Basal Cell Carcinoma Preceding Excision by Mohs Micrographic Surgery

This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

18

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Forenede Stater
    • Arizona
      • Scottsdale, Arizona, Forenede Stater, 85259
        • Mayo Clinic
    • California
      • Beverly Hills, California, Forenede Stater, 90210
        • Moy-Fincher-Chipps Facial Plastics and Dermatology
      • La Jolla, California, Forenede Stater, 92037
        • Scripps Clinic
      • Loma Linda, California, Forenede Stater, 92354
        • Loma Linda University Medical Center
      • Palo Alto, California, Forenede Stater, 94305
        • Stanford University
      • San Francisco, California, Forenede Stater, 94107
        • California Pacific Medical Center
      • San Francisco, California, Forenede Stater, 94115
        • Univ of Calif-San Francisco
    • Florida
      • St. Petersburg, Florida, Forenede Stater, 33716
        • Spencer Derma & Skin Surg Ctr
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60611
        • Northwestern University
    • Indiana
      • Carmel, Indiana, Forenede Stater, 46032
        • Laser & Skin Surgery Center of Indiana
    • Minnesota
      • Minneapolis, Minnesota, Forenede Stater, 55455
        • University of Minnesota
    • New York
      • New York, New York, Forenede Stater, 10011
        • Beth Israel Cancer Center; West Campus
      • Rochester, New York, Forenede Stater, 14642
        • University of Rochester Medical Center; University Dermatology Associates
      • West Islip, New York, Forenede Stater, 11795
        • Mariwalla Dermatology
    • North Carolina
      • Winston-Salem, North Carolina, Forenede Stater, 27106
        • The Skin Surgery Center
    • Oregon
      • Portland, Oregon, Forenede Stater, 97239-4501
        • Oregon Health & Science University; Department of Dermatology
    • Pennsylvania
      • Hershey, Pennsylvania, Forenede Stater, 17033
        • Penn State Milton S. Hershey Medical Center
      • Philadelphia, Pennsylvania, Forenede Stater, 19111
        • Fox Chase Cancer Center
    • Texas
      • Houston, Texas, Forenede Stater, 77030-4095
        • MD Anderson Cancer Center
    • Utah
      • Salt Lake City, Utah, Forenede Stater, 84112
        • Huntsman Cancer Institute at the University of Utah
    • Wisconsin
      • Madison, Wisconsin, Forenede Stater, 53792
        • University of Wisconsin

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Diagnosis of non-infected, not recurrent, previously untreated basal cell carcinoma
  • Free of any significant physical abnormalities (e.g., tattoos) at the target basal cell carcinoma site
  • Willing and able to participate in the study as an outpatient and agreement to make frequent visits to the clinic during the treatment and follow-up periods and to comply with study requirements

Exclusion Criteria:

  • Prior treatment with vismodegib
  • Known hypersensitivity to any of the study drug excipients
  • Any metastatic basal cell carcinoma
  • Any locally advanced basal cell carcinoma considered to be inoperable or to have a medical contraindication to surgery
  • Evidence of clinically significant and unstable diseases or conditions (e.g., cardiovascular, immunosuppressive, hematologic)
  • Any dermatological disease at the target basal cell carcinoma site that may cause difficulty with examination
  • Recent, current, or planned participation in another experimental drug study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Dobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo
Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks.
Medicin: Placebo
Participants will receive matching placebo to vismodegib for 12 weeks.
Eksperimentel: Vismodegib
Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.
Medicin: Vismodegib
Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Percent Change in Target Basal Cell Carcinoma (BCC) Expected Surgical Defect Area at Mohs Micrographic Surgery (MMS) Visit
Tidsramme: Baseline, MMS visit (Week 12-14)
The percent change in target BCC expected surgical defect area was defined as ([baseline expected surgical defect area - expected surgical defect area at MMS visit]/ baseline expected surgical defect area) × 100 percent (%) where expected surgical defect area was manually outlined on a digital photograph and measured by a computer (computer aided planimetry). MMS visit was defined as the visit that occurred within 2 weeks of the last study treatment.
Baseline, MMS visit (Week 12-14)

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Actual Change in Target BCC Expected Surgical Defect Area at MMS Visit
Tidsramme: Baseline, MSS Visit (Week 12-14)
Actual change was defined as (baseline expected surgical defect area - expected surgical defect area at MMS visit). MMS visit was defined as the visit that occurred within 2 weeks of the last study treatment. Expected surgical defect area was manually outlined on a digital photograph and measured by a computer (computer aided planimetry).
Baseline, MSS Visit (Week 12-14)
Percentage Change in Target BCC Actual Tumor-Free Margin Excision Area at MMS Visit
Tidsramme: Baseline, MMS visit (Week 12-14)
Percent change in target BCC actual tumor-free margin excision area was defined as = (expected surgical defect area pre-treatment - actual tumor-free margin excision area at MMS visit) / expected surgical defect area pre-treatment) * 100%. The actual tumor-free margin excision area (includes 2 millimeters [mm] margin) was measured during MMS. The area was photographed and traced on the digital photograph then calculated by computer-aided planimetry. MMS visit was defined as the visit that occurred within 2 weeks of the last study treatment.
Baseline, MMS visit (Week 12-14)
Percentage of Participants With Clinical Response
Tidsramme: MMS visit (Week 12-14)
Clinical response was defined as a complete response (CR) or partial response (PR) at the post-treatment MMS excision. CR was defined as no histological evidence of BCC. PR was defined as a reduction of at least 50 % in the expected surgical defect area with histologic evidence of residual BCC. MMS visit was defined the visit that occurred within 2 weeks of the last study treatment.
MMS visit (Week 12-14)
Percentage of Participants With Skip Area
Tidsramme: MMS visit (Week 12-14)
Skip area was defined as the presence of non-contiguous residual tumor at the MMS visit, as determined by an independent dermatopathologist. MMS visit occurred within 2 weeks of the last study treatment.
MMS visit (Week 12-14)
Percentage of Participants With BCC Recurrence
Tidsramme: Baseline, 12, 24, and 52 weeks post MMS Visit (MMS Visit = Week 12-14)
Baseline, 12, 24, and 52 weeks post MMS Visit (MMS Visit = Week 12-14)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Hoffmann-La Roche

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

23. januar 2014

Primær færdiggørelse (Faktiske)

26. januar 2016

Studieafslutning (Faktiske)

26. januar 2016

Datoer for studieregistrering

Først indsendt

3. juli 2013

Først indsendt, der opfyldte QC-kriterier

9. juli 2013

Først opslået (Skøn)

12. juli 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. maj 2017

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

27. marts 2017

Sidst verificeret

1. marts 2017

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • ML28726

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Basalcellekarcinom

Kliniske forsøg med Placebo

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Denmark

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner